ID

31344

Description

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period; ODM derived from: https://clinicaltrials.gov/show/NCT00560508

Link

https://clinicaltrials.gov/show/NCT00560508

Keywords

Versions (1)
  1. 8/16/18 8/16/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

August 16, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Parkinson Disease NCT00560508

English

Eligibility Parkinson Disease NCT00560508

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. male or female patients with diagnosis of pd including juvenile parkinsonism, in whom the onset began at the age of forty or younger.
Description

Parkinson Disease | Parkinsonism, Juvenile

Data type

boolean

Alias
UMLS CUI [1]
C0030567
UMLS CUI [2]
C0752105
2. patients with a modified hoehn and yahr scale of ii to iv at "on" time.
Description

Modified Hoehn and Yahr Scale score

Data type

boolean

Alias
UMLS CUI [1]
C4274318
3. patients who have received an individual dosage of l-dopa (either standard l-dopa or l-dopa with dopa-decarboxylase inhibitor) at a stable dose for at least 4 weeks before the baseline visit (visit 2).
Description

Levodopa Dose Stable | Levodopa Associated with DOPA Decarboxylase Inhibitors

Data type

boolean

Alias
UMLS CUI [1,1]
C0023570
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2,1]
C0023570
UMLS CUI [2,2]
C0332281
UMLS CUI [2,3]
C0598272
4. patients who exhibit any therapeutically problematic issues or status based on l-dopa therapy:
Description

Levodopa | Problem Therapeutic

Data type

boolean

Alias
UMLS CUI [1]
C0023570
UMLS CUI [2,1]
C0033213
UMLS CUI [2,2]
C0302350
wearing-off phenomena
Description

Wearing off effect

Data type

boolean

Alias
UMLS CUI [1]
C1504539
no on /delayed on
Description

Optic Neuritis Absent | Optic Neuritis Delayed

Data type

boolean

Alias
UMLS CUI [1,1]
C0029134
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0029134
UMLS CUI [2,2]
C0205421
dystonia at off time
Description

Dystonia

Data type

boolean

Alias
UMLS CUI [1]
C0013421
on-off phenomena
Description

On - off phenomenon

Data type

boolean

Alias
UMLS CUI [1]
C0852903
freezing phenomena at off time
Description

Freezing phenomenon

Data type

boolean

Alias
UMLS CUI [1]
C1262022
the sub-optimal dose of l-dopa had been administered due to side effects (such as dyskinesia), or therapeutical strategy
Description

Levodopa Dose Suboptimal | Etiology Adverse effects | Dyskinetic syndrome

Data type

boolean

Alias
UMLS CUI [1,1]
C0023570
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C2984009
UMLS CUI [2,1]
C0015127
UMLS CUI [2,2]
C0879626
UMLS CUI [3]
C0013384
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases.
Description

Parkinsonian Disorders Atypical Drug-induced | Parkinsonian Disorders Atypical Due to Metabolic Diseases | Parkinsonian Disorders Atypical Due to Encephalitis | Parkinsonian Disorders Atypical Due to Degenerative disorder

Data type

boolean

Alias
UMLS CUI [1,1]
C0242422
UMLS CUI [1,2]
C0205182
UMLS CUI [1,3]
C0458082
UMLS CUI [2,1]
C0242422
UMLS CUI [2,2]
C0205182
UMLS CUI [2,3]
C0678226
UMLS CUI [2,4]
C0025517
UMLS CUI [3,1]
C0242422
UMLS CUI [3,2]
C0205182
UMLS CUI [3,3]
C0678226
UMLS CUI [3,4]
C0014038
UMLS CUI [4,1]
C0242422
UMLS CUI [4,2]
C0205182
UMLS CUI [4,3]
C0678226
UMLS CUI [4,4]
C1285162
2. dementia, as defined by a mini-mental state examination (mmse) score <24 at screening visit.
Description

Dementia Mini-mental state examination

Data type

boolean

Alias
UMLS CUI [1,1]
C0497327
UMLS CUI [1,2]
C0451306
3. any psychiatric disorder according to dsm-iv criteria that could prevent compliance or completion of the trial and/or put the patient at risk if he/she takes part in the trial.
Description

Mental disorders Preventing Compliance behavior | Mental disorders Preventing Completion of clinical trial | Mental disorders Study Subject Participation Status At risk

Data type

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C1292733
UMLS CUI [1,3]
C1321605
UMLS CUI [2,1]
C0004936
UMLS CUI [2,2]
C1292733
UMLS CUI [2,3]
C2732579
UMLS CUI [3,1]
C0004936
UMLS CUI [3,2]
C2348568
UMLS CUI [3,3]
C1444641
4. history of psychosis, except history of drug induced hallucinations (provided the investigator considers that participation in the trial would not represent a significant risk for the patient).
Description

Psychotic Disorders | Exception Drug-induced hallucinations

Data type

boolean

Alias
UMLS CUI [1]
C0033975
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1456732
5. clinically significant ecg abnormalities at screening visit, according to investigator's judgement.
Description

Electrocardiogram abnormal

Data type

boolean

Alias
UMLS CUI [1]
C0522055
6. clinically significant hypotension or symptomatic orthostatic hypotension (i.e., clinical symptoms of orthostatic hypotension such as dizziness postural etc associated with a decline >=20 mmhg in systolic blood pressure and a decline >=10 mmhg in diastolic blood pressure, at one minute after standing compared with the previous supine systolic and diastolic blood pressure obtained after 5 minutes of quiet rest) either at screening visit or at baseline visit.
Description

Hypotension | Hypotension orthostatic symptomatic | Postural dizziness | Decreased systolic arterial pressure | Decreased diastolic arterial pressure | Lying systolic blood pressure Post Rest | Lying diastolic blood pressure Post Rest

Data type

boolean

Alias
UMLS CUI [1]
C0020649
UMLS CUI [2]
C0740482
UMLS CUI [3]
C0234987
UMLS CUI [4]
C0277885
UMLS CUI [5]
C0277890
UMLS CUI [6,1]
C1319895
UMLS CUI [6,2]
C0687676
UMLS CUI [6,3]
C0035253
UMLS CUI [7,1]
C1319896
UMLS CUI [7,2]
C0687676
UMLS CUI [7,3]
C0035253
7. any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the trial.
Description

Disease At risk Patient | Disease Preventing Compliance behavior | Disease Preventing Completion of clinical trial

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C0030705
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C1292733
UMLS CUI [2,3]
C1321605
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C1292733
UMLS CUI [3,3]
C2732579
8. pregnancy (to be excluded by serum pregnancy test at screening visit) or breast-feeding.
Description

Pregnancy Serum pregnancy test | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0430064
UMLS CUI [2]
C0006147
9. sexually active female of childbearing potential not using a medically approved method of birth control within one month before to the screening visit and throughout the trial period.
Description

Gender Sexually active | Childbearing Potential Contraceptive methods Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0241028
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0700589
UMLS CUI [2,3]
C0332197
10. serum levels of ast, alt, alkaline phosphatases or bilirubin >2 upper limits of normal .
Description

Aspartate aminotransferase increased | Alanine aminotransferase increased | Alkaline phosphatase raised | Serum bilirubin increased

Data type

boolean

Alias
UMLS CUI [1]
C0151904
UMLS CUI [2]
C0151905
UMLS CUI [3]
C0151849
UMLS CUI [4]
C0859062
11. patients with a creatinine clearance <50 ml/min
Description

Creatinine clearance measurement

Data type

boolean

Alias
UMLS CUI [1]
C0373595
12. patients with a complication or signs of malignant tumours or those within 5 years after the treatment.
Description

Complication | Signs Malignant Neoplasms

Data type

boolean

Alias
UMLS CUI [1]
C0009566
UMLS CUI [2,1]
C0311392
UMLS CUI [2,2]
C0006826
Back to the top of the page

Similar models

Eligibility Parkinson Disease NCT00560508

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Parkinson Disease | Parkinsonism, Juvenile
Item
1. male or female patients with diagnosis of pd including juvenile parkinsonism, in whom the onset began at the age of forty or younger.
boolean
C0030567 (UMLS CUI [1])
C0752105 (UMLS CUI [2])
Modified Hoehn and Yahr Scale score
Item
2. patients with a modified hoehn and yahr scale of ii to iv at "on" time.
boolean
C4274318 (UMLS CUI [1])
Levodopa Dose Stable | Levodopa Associated with DOPA Decarboxylase Inhibitors
Item
3. patients who have received an individual dosage of l-dopa (either standard l-dopa or l-dopa with dopa-decarboxylase inhibitor) at a stable dose for at least 4 weeks before the baseline visit (visit 2).
boolean
C0023570 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0023570 (UMLS CUI [2,1])
C0332281 (UMLS CUI [2,2])
C0598272 (UMLS CUI [2,3])
Levodopa | Problem Therapeutic
Item
4. patients who exhibit any therapeutically problematic issues or status based on l-dopa therapy:
boolean
C0023570 (UMLS CUI [1])
C0033213 (UMLS CUI [2,1])
C0302350 (UMLS CUI [2,2])
Wearing off effect
Item
wearing-off phenomena
boolean
C1504539 (UMLS CUI [1])
Optic Neuritis Absent | Optic Neuritis Delayed
Item
no on /delayed on
boolean
C0029134 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0029134 (UMLS CUI [2,1])
C0205421 (UMLS CUI [2,2])
Dystonia
Item
dystonia at off time
boolean
C0013421 (UMLS CUI [1])
On - off phenomenon
Item
on-off phenomena
boolean
C0852903 (UMLS CUI [1])
Freezing phenomenon
Item
freezing phenomena at off time
boolean
C1262022 (UMLS CUI [1])
Levodopa Dose Suboptimal | Etiology Adverse effects | Dyskinetic syndrome
Item
the sub-optimal dose of l-dopa had been administered due to side effects (such as dyskinesia), or therapeutical strategy
boolean
C0023570 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C2984009 (UMLS CUI [1,3])
C0015127 (UMLS CUI [2,1])
C0879626 (UMLS CUI [2,2])
C0013384 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Parkinsonian Disorders Atypical Drug-induced | Parkinsonian Disorders Atypical Due to Metabolic Diseases | Parkinsonian Disorders Atypical Due to Encephalitis | Parkinsonian Disorders Atypical Due to Degenerative disorder
Item
1. atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases.
boolean
C0242422 (UMLS CUI [1,1])
C0205182 (UMLS CUI [1,2])
C0458082 (UMLS CUI [1,3])
C0242422 (UMLS CUI [2,1])
C0205182 (UMLS CUI [2,2])
C0678226 (UMLS CUI [2,3])
C0025517 (UMLS CUI [2,4])
C0242422 (UMLS CUI [3,1])
C0205182 (UMLS CUI [3,2])
C0678226 (UMLS CUI [3,3])
C0014038 (UMLS CUI [3,4])
C0242422 (UMLS CUI [4,1])
C0205182 (UMLS CUI [4,2])
C0678226 (UMLS CUI [4,3])
C1285162 (UMLS CUI [4,4])
Dementia Mini-mental state examination
Item
2. dementia, as defined by a mini-mental state examination (mmse) score <24 at screening visit.
boolean
C0497327 (UMLS CUI [1,1])
C0451306 (UMLS CUI [1,2])
Mental disorders Preventing Compliance behavior | Mental disorders Preventing Completion of clinical trial | Mental disorders Study Subject Participation Status At risk
Item
3. any psychiatric disorder according to dsm-iv criteria that could prevent compliance or completion of the trial and/or put the patient at risk if he/she takes part in the trial.
boolean
C0004936 (UMLS CUI [1,1])
C1292733 (UMLS CUI [1,2])
C1321605 (UMLS CUI [1,3])
C0004936 (UMLS CUI [2,1])
C1292733 (UMLS CUI [2,2])
C2732579 (UMLS CUI [2,3])
C0004936 (UMLS CUI [3,1])
C2348568 (UMLS CUI [3,2])
C1444641 (UMLS CUI [3,3])
Psychotic Disorders | Exception Drug-induced hallucinations
Item
4. history of psychosis, except history of drug induced hallucinations (provided the investigator considers that participation in the trial would not represent a significant risk for the patient).
boolean
C0033975 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1456732 (UMLS CUI [2,2])
Electrocardiogram abnormal
Item
5. clinically significant ecg abnormalities at screening visit, according to investigator's judgement.
boolean
C0522055 (UMLS CUI [1])
Hypotension | Hypotension orthostatic symptomatic | Postural dizziness | Decreased systolic arterial pressure | Decreased diastolic arterial pressure | Lying systolic blood pressure Post Rest | Lying diastolic blood pressure Post Rest
Item
6. clinically significant hypotension or symptomatic orthostatic hypotension (i.e., clinical symptoms of orthostatic hypotension such as dizziness postural etc associated with a decline >=20 mmhg in systolic blood pressure and a decline >=10 mmhg in diastolic blood pressure, at one minute after standing compared with the previous supine systolic and diastolic blood pressure obtained after 5 minutes of quiet rest) either at screening visit or at baseline visit.
boolean
C0020649 (UMLS CUI [1])
C0740482 (UMLS CUI [2])
C0234987 (UMLS CUI [3])
C0277885 (UMLS CUI [4])
C0277890 (UMLS CUI [5])
C1319895 (UMLS CUI [6,1])
C0687676 (UMLS CUI [6,2])
C0035253 (UMLS CUI [6,3])
C1319896 (UMLS CUI [7,1])
C0687676 (UMLS CUI [7,2])
C0035253 (UMLS CUI [7,3])
Disease At risk Patient | Disease Preventing Compliance behavior | Disease Preventing Completion of clinical trial
Item
7. any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the trial.
boolean
C0012634 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0030705 (UMLS CUI [1,3])
C0012634 (UMLS CUI [2,1])
C1292733 (UMLS CUI [2,2])
C1321605 (UMLS CUI [2,3])
C0012634 (UMLS CUI [3,1])
C1292733 (UMLS CUI [3,2])
C2732579 (UMLS CUI [3,3])
Pregnancy Serum pregnancy test | Breast Feeding
Item
8. pregnancy (to be excluded by serum pregnancy test at screening visit) or breast-feeding.
boolean
C0032961 (UMLS CUI [1,1])
C0430064 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
Gender Sexually active | Childbearing Potential Contraceptive methods Absent
Item
9. sexually active female of childbearing potential not using a medically approved method of birth control within one month before to the screening visit and throughout the trial period.
boolean
C0079399 (UMLS CUI [1,1])
C0241028 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
Aspartate aminotransferase increased | Alanine aminotransferase increased | Alkaline phosphatase raised | Serum bilirubin increased
Item
10. serum levels of ast, alt, alkaline phosphatases or bilirubin >2 upper limits of normal .
boolean
C0151904 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
C0151849 (UMLS CUI [3])
C0859062 (UMLS CUI [4])
Creatinine clearance measurement
Item
11. patients with a creatinine clearance <50 ml/min
boolean
C0373595 (UMLS CUI [1])
Complication | Signs Malignant Neoplasms
Item
12. patients with a complication or signs of malignant tumours or those within 5 years after the treatment.
boolean
C0009566 (UMLS CUI [1])
C0311392 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial